[
  {
    "ts": null,
    "headline": "Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?",
    "summary": "CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.",
    "url": "https://finnhub.io/api/news?id=5e0834c0db10ab0c42d2b6110d323f769a2dafa108c3be3b657e29ad27a6c11c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769183940,
      "headline": "Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?",
      "id": 138227029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.",
      "url": "https://finnhub.io/api/news?id=5e0834c0db10ab0c42d2b6110d323f769a2dafa108c3be3b657e29ad27a6c11c"
    }
  },
  {
    "ts": null,
    "headline": "The Top Stock to Buy With $30 for 2026",
    "summary": "It's a great opportunity to \"buy low.\"",
    "url": "https://finnhub.io/api/news?id=a1b989df27d37a127721101b54d6ae8b5002943670e937e9b90f18f3a3f645a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769181600,
      "headline": "The Top Stock to Buy With $30 for 2026",
      "id": 138225735,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "It's a great opportunity to \"buy low.\"",
      "url": "https://finnhub.io/api/news?id=a1b989df27d37a127721101b54d6ae8b5002943670e937e9b90f18f3a3f645a9"
    }
  },
  {
    "ts": null,
    "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings",
    "summary": "LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.",
    "url": "https://finnhub.io/api/news?id=9b077c59e797e4ea01bcd54334d200de183be16426ec55c70fc8dec1828a99b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769175360,
      "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings",
      "id": 138225631,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.",
      "url": "https://finnhub.io/api/news?id=9b077c59e797e4ea01bcd54334d200de183be16426ec55c70fc8dec1828a99b0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)",
    "summary": "Pfizer (PFE) is a Buy before Q1 2027 earnings: discounted shares, cost cuts and pipeline catalysts may offset LOE, support dividends, and drive upsideâread...",
    "url": "https://finnhub.io/api/news?id=226c2110c4fb0ed52507351082420824d5f2fc94a7e3e759e6323b02b18a8501",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769164418,
      "headline": "Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)",
      "id": 138225463,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer (PFE) is a Buy before Q1 2027 earnings: discounted shares, cost cuts and pipeline catalysts may offset LOE, support dividends, and drive upsideâread...",
      "url": "https://finnhub.io/api/news?id=226c2110c4fb0ed52507351082420824d5f2fc94a7e3e759e6323b02b18a8501"
    }
  },
  {
    "ts": null,
    "headline": "December Readers ID'd 9 Ideal 'Safer' Dividends In 40 Dogs",
    "summary": "December Readers ID'd 9 Ideal 'Safer' Dividends In 40 Dogs",
    "url": "https://finnhub.io/api/news?id=902e79f8c9e0fe52d1a3693e35ba8b469f2b4bc48e5d46b6cedcb2bb2602762c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769162061,
      "headline": "December Readers ID'd 9 Ideal 'Safer' Dividends In 40 Dogs",
      "id": 138225275,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=902e79f8c9e0fe52d1a3693e35ba8b469f2b4bc48e5d46b6cedcb2bb2602762c"
    }
  },
  {
    "ts": null,
    "headline": "Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy?",
    "summary": "Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to use its Matrix-M adjuvant in vaccine products for up to two infectious disease areas, in return for a US$30 million upfront payment plus potential milestones and royalties. The deal effectively lets Pfizer plug a proven third-party adjuvant into its own vaccine platforms while keeping full control over development, manufacturing, and commercialization decisions. With...",
    "url": "https://finnhub.io/api/news?id=9b48c15700b62a618d31ae0997cffabeed522b92869e12a214816cd40ccb56f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769152574,
      "headline": "Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy?",
      "id": 138222088,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to use its Matrix-M adjuvant in vaccine products for up to two infectious disease areas, in return for a US$30 million upfront payment plus potential milestones and royalties. The deal effectively lets Pfizer plug a proven third-party adjuvant into its own vaccine platforms while keeping full control over development, manufacturing, and commercialization decisions. With...",
      "url": "https://finnhub.io/api/news?id=9b48c15700b62a618d31ae0997cffabeed522b92869e12a214816cd40ccb56f2"
    }
  },
  {
    "ts": null,
    "headline": "What obesity drugmakers see next in the market: More pills, easier access and drug combinations",
    "summary": "CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.",
    "url": "https://finnhub.io/api/news?id=e69a89e18c4ccf186242eb8613a7743e95e35683e2a2e2fc6f3f0e07e1f5616c",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769151601,
      "headline": "What obesity drugmakers see next in the market: More pills, easier access and drug combinations",
      "id": 138226467,
      "image": "https://image.cnbcfm.com/api/v1/image/108253253-1768511651216-gettyimages-2255813292-WEGOVY_PILLS.jpeg?v=1769106872&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco. ",
      "url": "https://finnhub.io/api/news?id=e69a89e18c4ccf186242eb8613a7743e95e35683e2a2e2fc6f3f0e07e1f5616c"
    }
  }
]